カテゴリ： GlobalData, イギリス, 企業調査

Cancer Research UK-製薬・医療分野：企業M&A・提携分析

◆英語タイトル：Cancer Research UK - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード：DATA8011793
◆発行会社（調査会社）：GlobalData
◆発行日：2017年12月13日
◆ページ数：157
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：イギリス
◆産業分野：製薬・医療
◆販売価格オプション（消費税別）
Single UserUSD250 ⇒換算￥37,000見積依頼/購入/質問フォーム
Site License（同一事業所内共有可）USD500 ⇒換算￥74,000見積依頼/購入/質問フォーム
Enterprisewide License（複数事業所内共有可）USD750 ⇒換算￥111,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※GlobalData社の概要はこちらでご確認いただけます。

このエントリーをはてなブックマークに追加
LINEで送る


【レポートの概要】

Summary
Cancer Research UK (CRUK) is a research institution which offers clinical research services to treat cancer. The institute offers research services for womb cancer, lung cancer, bladder cancer, bone cancer, bowel cancer, brain tumours, breast cancer, carcinoid, cervical cancer, children’s cancer, choriocarcinoma, chronic lymphocytic leukaemia, chronic myeloid leukaemia, colon cancer, colorectal cancer, endometrial cancer, eye cancer, gallbladder cancer and gastric cancer among others. CRUK cancer treatment services comprises of symptoms research, screening, tests, treatment and clinical trial services. The institute also conducts research in the areas of Cancer biology, Cancer drugs, Clinical trials, Radiotherapy, Immunotherapy among others. CRUK is headquartered in London, the UK.

Cancer Research UK – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 6
List of Figures 7
Cancer Research UK, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 8
Cancer Research UK, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 9
Cancer Research UK, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 10
Cancer Research UK, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 11
Cancer Research UK, Medical Devices Deals, 2011 to YTD 2017 12
Cancer Research UK, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 13
Cancer Research UK, Pharmaceuticals & Healthcare, Deal Details 18
Venture Financing 18
GammaDelta Therapeutics Raises Funds through Seed Financing 18
ADC Therapeutics To Raise US$50 Million In Venture Financing 19
BliNK Therapeutics Secures US$1.78 Million In Seed Financing 21
Partnerships 22
Cancer Research UK and Biotecnol Enter into Agreement 22
Cancer Research Technology Enters into Agreement with Merck 23
Tusk Therapeutics Enters into Agreement with University College London and Cancer Research Technology 24
Cancer Research UK Enters into Agreement with Bicycle Therapeutics 25
Cancer Research UK, Cancer Research Technology to Enter into Agreement with TYG Oncology 26
Merck Sharp & Dohme, Verastem and Cancer Research UK Enter into Agreement 27
Artios Pharma Research Agreement with Cancer Research Technology 28
CiMaas Enters into Agreement with Cancer Research Technology and University of Copenhagen 29
Cell Therapy Catapult Enters into Joint venture Agreement with University of Birmingham and Cancer Research Technology 30
Cancer Research UK Enters into Research Agreement with OHSU Knight Cancer Institute 31
Monopar Therapeutics Enters into Agreement with Cancer Research UK and Cancer Research Technology 32
Medivir Enters into Development Agreement with Cancer Research Technology 33
BioInvent and CRT Enter into Research Agreement with University of Southampton 34
Cancer Research UK Forms Joint Venture with MedImmune 35
Cancer Research and Cancer Research Technology Enter into Co-Development Agreement with Astellas Pharma 36
Nuevolution Enters Into Agreement With Cancer Research Technology And Institute Of Cancer Research For Drug Discovery 37
Cancer Research UK Enters Into Co-Development Agreement With AstraZeneca 39
Cancer Research UK And Eli Lilly Enter Into Agreement To Discover Cancer Treatments 40
GlaxoSmithKline Enters Into Agreement With Cancer Research Technology And University of Manchester For Cancer Drugs 41
HitGen Enters into Drug Discovery Agreement with Cancer Research UK and Cancer Research Technology 42
Cancer Research Technology Enters Into Agreement With Nuevolution For Anti-Cancer Drug Molecule Discovery 43
Cancer Research Technology And Teva Enter Into R&D Agreement To Develop Cancer Drugs 44
Cancer Research Technology And Institute of Cancer Research Enter Into Agreement With Merck Serono For Drug Discovery 45
Forma Therapeutics Expands Discovery Agreement with Cancer Research Technology 46
Cancer Research Technology, University of Manchester And AstraZeneca Enters Into Agreement To Develop Cancer Drugs 47
Janssen Biotech Enters Into Agreement With CRT And ICR To Discover Multiple Myeloma Drug 48
Cancer Research Technology And AstraZeneca Extend Co-Development Agreement For Anti-Cancer Drugs 49
Cancer Research UK Enters Into Co-Development Agreement With Lorus To Develop Cancer Drug 50
Astex Pharma, Cancer Research Technology And Newcastle University Enter Into Drug Discovery Agreement 52
Astex Pharma, Cancer Research Technology And Institute of Cancer Research Enter Into Epigenetic Drug Discovery Agreement 54
Cancer Research Technology Enters Into Co-Development Agreement With ADC Therapeutics For Antibody Drug Conjugates 56
BioInvent And Cancer Research Technology Enter Into Co-Development Agreement With Queen Mary, University of London 58
Cancer Research UK Enters Into Co-Development Agreement With Centella Therapeutics And Cancer Research Technology 60
Cancer Research UK Enters Into Joint Venture Agreement With University Of Oxford And Oxford Radcliffe 61
Cancer Research Technology, Institute of Cancer Research And ZoBio Enter Into Agreement To Develop Cancer Drugs 62
MdxHealth Enters Into Co-Development Agreement With Newcastle University, Cancer Research Technology And Pfizer 63
Licensing Agreements 65
Glythera Enters into Licensing Agreement with Cancer Research UK 65
Cancer Research UK and Cancer Research Technology Enter into Licensing Agreement with HitGen 66
Tusk Therapeutics Enters into Licensing Agreement with University College London and Cancer Research Technology 67
Achilles Therapeutics Receives Rights to Develop Immunotherapies for Cancer 68
Storm Therapeutics Receives Intellectual Property Rights from University of Cambridge and Cancer Research UK 69
Cancer Research Technology Enters into Licensing Agreement with Pangaea Biotech 70
Merck Enters into Licensing Agreement with Cancer Research Technology 71
Basilea Pharma Enters into Licensing Agreement for Novel PanRAF Kinase Inhibitors 72
Cancer Research UK Enters into Licensing Agreement with Amgen 73
Immatics Biotech, Cancer Research UK and Cancer Research Technology Enter into Licensing Agreement 74
Artios Pharma Enters into Licensing Agreement with Cancer Research Technology 75
BioInvent Enters into Licensing Agreement with University of Southampton and Cancer Research Technology 76
Nemucore Medical Innovations Enters into Licensing Agreement with Cancer Research Technology 77
Epistem Holdings and CRT Enter into Licensing Agreement with Newcastle University 78
Alchemia Enters Into Licensing Agreement With Cancer Research Technology For FAK Inhibitors 79
Cancer Research Technology, Cardiff University, And Institute of Cancer Research Extend Licensing Agreement With Merck Serono 80
Affitech Enters Into Licensing Agreement With Cancer Research Technology 82
Equity Offering 83
iOnctura Spin Out from Merck and Cancer Research Technology 83
Cancer Research UK – Key Competitors 84
Cancer Research UK – Key Employees 85
Cancer Research UK – Locations And Subsidiaries 86
Head Office 86
Other Locations & Subsidiaries 86
Joint Venture 86
Recent Developments 87
Research And Development 87
Jun 29, 2016: Cancer Research UK joins forces with U.S. ‘Cancer Moonshot’ to develop advanced cancer cell detection technology 87
Corporate Communications 89
Apr 28, 2016: Cancer Research UK announces appointment of new Chairman 89
Government and Public Interest 90
Nov 30, 2017: Tackling ‘undruggable’ genes in lung and pancreatic cancers is this researcher’s life 90
Nov 30, 2017: Immune-boosting antibody combination could improve lymphoma survival 94
Nov 03, 2017: More women than men are diagnosed with bowel cancer as an emergency despite extra GP visits 95
Nov 02, 2017: Gut bacteria may influence response to cancer immunotherapy 96
Nov 02, 2017: Scientists awarded £1.5m for pioneering bowel cancer research 97
Nov 01, 2017: Alternative cancer therapies: the potential impact on survival 98
Oct 27, 2017: Safety of gene therapy for brain tumours tested in early trial 101
Oct 26, 2017: £800K Boost for Queen’s University Researchers to Improve Bowel Cancer Treatment 102
Oct 24, 2017: Some aggressive ovarian cancers start in the fallopian tubes, not the ovaries 104
Oct 24, 2017: Internal radiotherapy: tackling cancer from within 106
Oct 18, 2017: Researchers “drug the undruggable” through unique collaboration 108
Oct 05, 2017: Some cancer drugs approved in Europe might not have sufficient evidence of survival benefits, says study 109
Sep 17, 2017: £2million award for cancer researcher 111
Sep 15, 2017: New funding to unite transatlantic forces for the early detection of cancer 112
Sep 08, 2017: Viruses may boost immunotherapy success 113
Sep 08, 2017: Targeted drug helps keep some advanced ovarian cancers at bay 115
Sep 08, 2017: Two treatments for advanced prostate cancer bring equal benefits 116
Sep 05, 2017: New approach could better predict breast cancer risk due to family history 117
Aug 30, 2017: Early detection of cancer highlighted in new life sciences industrial strategy 119
Aug 22, 2017: Studies highlight ‘potential new targets for immunotherapy’ 120
Aug 17, 2017: New Way To Empower The Immune System To Detect And Kill Cancer 121
Aug 03, 2017: Scientists deliver knock-out blow to multiple cancers 122
Aug 02, 2017: Targeted radiotherapy limits side effects of breast cancer treatment 123
Jul 13, 2017: Scientists make breakthrough in reversing treatment resistance in blood cancer patients 125
Jun 19, 2017: Discovery could guide immunotherapy for lung cancer 127
May 19, 2017: Scientists to test Zika virus on brain tumours 128
Apr 19, 2017: CRT pioneer fund, Cancer Research UK and NCI collaborate to boost research against the ‘undruggable’ RAS 129
Feb 10, 2017: U.S. Scientists Receive Inaugural $87 Million Grand Challenge Awards To Accelerate Global Progress To Beat Cancer Sooner 130
Feb 01, 2017: Cancer Research: Big data brings breast cancer research forwards by ‘decades’ 131
Dec 13, 2016: New research provides hope for patients with hard-to-treat breast cancer 132
Nov 09, 2016: Marker for aggressive prostate cancer doubles-up as a drug target 133
Sep 14, 2016: New Way Of Testing Drugs Could Speed Up Development Of Breast Cancer Treatments 134
Aug 04, 2016: Cancer Research UK reaches landmark fundraising target of £100 million to help complete the Francis Crick Institute 135
Jun 03, 2016: Cancer Research UK trial shows improved 5 year survival for pancreatic cancer patients 137
Jun 02, 2016: Scientists tear down pancreatic cancer’s defences 138
May 24, 2016: Vitamin A may help improve pancreatic cancer chemotherapy 139
Apr 15, 2016: Gene editing could stop cancer cells escaping the immune system 140
Mar 07, 2016: Blood test may give early warning of skin cancer relapse 141
Feb 25, 2016: Pancreatic cancer found to be four separate diseases 142
Jan 19, 2016: Scientists find new gene fault behind ovarian cancer 143
Product News 144
Nov 24, 2017: Experimental drug trial seeks to improve treatment for head and neck cancer 144
Aug 24, 2016: Scientists Discover Drug Combination Slows Lung Cancer Cell Growth 145
Jun 08, 2016: Bubbly drinks inspire more effective cancer treatment 146
Jun 06, 2017: New chemotherapy approach offers breast cancer patients a better quality of life 147
Mar 14, 2016: HIV drug could stop skin cancer becoming drug-resistant 148
Other Significant Developments 149
Dec 06, 2016: App launched to help doctors assess risk of lung cancer in people with lung nodules 149
Nov 30, 2016: £226 million UK investment in cancer research announced 150
May 27, 2016: International trial for children’s brain tumours launches in the UK 152
May 13, 2016: Cancer Research UK Invests £16 Million Into Hard To Treat Cancers 153
May 13, 2016: Post-mortem cancer study goes national 154
Jan 04, 2016: Biggest database for cancer drug discovery goes 3D 156
Appendix 157
Methodology 157
About GlobalData 157
Contact Us 157
Disclaimer 157

List of Tables
Cancer Research UK, Pharmaceuticals & Healthcare, Key Facts 2
Cancer Research UK, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 8
Cancer Research UK, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 9
Cancer Research UK, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 10
Cancer Research UK, Deals By Therapy Area, 2011 to YTD 2017 11
Cancer Research UK, Medical Devices Deals, 2011 to YTD 2017 12
Cancer Research UK, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 13
GammaDelta Therapeutics Raises Funds through Seed Financing 18
ADC Therapeutics To Raise US$50 Million In Venture Financing 19
BliNK Therapeutics Secures US$1.78 Million In Seed Financing 21
Cancer Research UK and Biotecnol Enter into Agreement 22
Cancer Research Technology Enters into Agreement with Merck 23
Tusk Therapeutics Enters into Agreement with University College London and Cancer Research Technology 24
Cancer Research UK Enters into Agreement with Bicycle Therapeutics 25
Cancer Research UK, Cancer Research Technology to Enter into Agreement with TYG Oncology 26
Merck Sharp & Dohme, Verastem and Cancer Research UK Enter into Agreement 27
Artios Pharma Research Agreement with Cancer Research Technology 28
CiMaas Enters into Agreement with Cancer Research Technology and University of Copenhagen 29
Cell Therapy Catapult Enters into Joint venture Agreement with University of Birmingham and Cancer Research Technology 30
Cancer Research UK Enters into Research Agreement with OHSU Knight Cancer Institute 31
Monopar Therapeutics Enters into Agreement with Cancer Research UK and Cancer Research Technology 32
Medivir Enters into Development Agreement with Cancer Research Technology 33
BioInvent and CRT Enter into Research Agreement with University of Southampton 34
Cancer Research UK Forms Joint Venture with MedImmune 35
Cancer Research and Cancer Research Technology Enter into Co-Development Agreement with Astellas Pharma 36
Nuevolution Enters Into Agreement With Cancer Research Technology And Institute Of Cancer Research For Drug Discovery 37
Cancer Research UK Enters Into Co-Development Agreement With AstraZeneca 39
Cancer Research UK And Eli Lilly Enter Into Agreement To Discover Cancer Treatments 40
GlaxoSmithKline Enters Into Agreement With Cancer Research Technology And University of Manchester For Cancer Drugs 41
HitGen Enters into Drug Discovery Agreement with Cancer Research UK and Cancer Research Technology 42
Cancer Research Technology Enters Into Agreement With Nuevolution For Anti-Cancer Drug Molecule Discovery 43
Cancer Research Technology And Teva Enter Into R&D Agreement To Develop Cancer Drugs 44
Cancer Research Technology And Institute of Cancer Research Enter Into Agreement With Merck Serono For Drug Discovery 45
Forma Therapeutics Expands Discovery Agreement with Cancer Research Technology 46
Cancer Research Technology, University of Manchester And AstraZeneca Enters Into Agreement To Develop Cancer Drugs 47
Janssen Biotech Enters Into Agreement With CRT And ICR To Discover Multiple Myeloma Drug 48
Cancer Research Technology And AstraZeneca Extend Co-Development Agreement For Anti-Cancer Drugs 49
Cancer Research UK Enters Into Co-Development Agreement With Lorus To Develop Cancer Drug 50
Astex Pharma, Cancer Research Technology And Newcastle University Enter Into Drug Discovery Agreement 52
Astex Pharma, Cancer Research Technology And Institute of Cancer Research Enter Into Epigenetic Drug Discovery Agreement 54
Cancer Research Technology Enters Into Co-Development Agreement With ADC Therapeutics For Antibody Drug Conjugates 56
BioInvent And Cancer Research Technology Enter Into Co-Development Agreement With Queen Mary, University of London 58
Cancer Research UK Enters Into Co-Development Agreement With Centella Therapeutics And Cancer Research Technology 60
Cancer Research UK Enters Into Joint Venture Agreement With University Of Oxford And Oxford Radcliffe 61
Cancer Research Technology, Institute of Cancer Research And ZoBio Enter Into Agreement To Develop Cancer Drugs 62
MdxHealth Enters Into Co-Development Agreement With Newcastle University, Cancer Research Technology And Pfizer 63
Glythera Enters into Licensing Agreement with Cancer Research UK 65
Cancer Research UK and Cancer Research Technology Enter into Licensing Agreement with HitGen 66
Tusk Therapeutics Enters into Licensing Agreement with University College London and Cancer Research Technology 67
Achilles Therapeutics Receives Rights to Develop Immunotherapies for Cancer 68
Storm Therapeutics Receives Intellectual Property Rights from University of Cambridge and Cancer Research UK 69
Cancer Research Technology Enters into Licensing Agreement with Pangaea Biotech 70
Merck Enters into Licensing Agreement with Cancer Research Technology 71
Basilea Pharma Enters into Licensing Agreement for Novel PanRAF Kinase Inhibitors 72
Cancer Research UK Enters into Licensing Agreement with Amgen 73
Immatics Biotech, Cancer Research UK and Cancer Research Technology Enter into Licensing Agreement 74
Artios Pharma Enters into Licensing Agreement with Cancer Research Technology 75
BioInvent Enters into Licensing Agreement with University of Southampton and Cancer Research Technology 76
Nemucore Medical Innovations Enters into Licensing Agreement with Cancer Research Technology 77
Epistem Holdings and CRT Enter into Licensing Agreement with Newcastle University 78
Alchemia Enters Into Licensing Agreement With Cancer Research Technology For FAK Inhibitors 79
Cancer Research Technology, Cardiff University, And Institute of Cancer Research Extend Licensing Agreement With Merck Serono 80
Affitech Enters Into Licensing Agreement With Cancer Research Technology 82
iOnctura Spin Out from Merck and Cancer Research Technology 83
Cancer Research UK, Key Competitors 84
Cancer Research UK, Key Employees 85
Cancer Research UK, Subsidiaries 86
Cancer Research UK, Joint Venture 86

★海外企業調査レポート[Cancer Research UK-製薬・医療分野：企業M&A・提携分析]についてメールでお問い合わせはこちら
■おすすめ企業レポート■
  • Synaffix BV：製薬・医療：M&Aディール及び事業提携情報
    Summary Synaffix BV (Synaffix) is a biotechnology company that discovers and develops site-specific antibody-drug conjugates technology platforms. The company develops its products through its proprietary technology and GlycoConnect. It constructs homogenous and stable ADCs with the aid of a payload …
  • The Centre of Excellence for Prevention of Organ Failure：医療機器：M&Aディール及び事業提携情報
    Summary The Centre of Excellence for Prevention of Organ Failure (PROOF Centre) is a healthcare center that provides blood-based biomarker tests. The center conducts biomarker programs to develop simple blood tests for transplant patients and patients with chronic organ disease and biomarkers in tra …
  • San Leon Energy Plc (SLE)：石油・ガス：M&Aディール及び事業提携情報
    Summary San Leon Energy Plc (San Leon) is an oil and gas exploration and production company. It is engaged in acquiring, exploring and developing conventional and shale oil and gas assets across Europe and North Africa. The company holds interests in Durresi Block located in offshore Albania and inc …
  • Viasat Inc：企業の戦略・SWOT・財務分析
    Viasat Inc - Strategy, SWOT and Corporate Finance Report Summary Viasat Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actio …
  • AEON Credit Service (M) Berhad：企業の戦略・SWOT・財務情報
    AEON Credit Service (M) Berhad - Strategy, SWOT and Corporate Finance Report Summary AEON Credit Service (M) Berhad - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …
  • Cheniere Energy Inc (LNG)：石油・ガス：M&Aディール及び事業提携情報
    Summary Cheniere Energy Inc (Cheniere) is a midstream energy company that owns and operates LNG-related businesses. The company through its general partner, Cheniere Energy Partners, L.P. (Cheniere Partners) and Cheniere Energy Partners LP Holdings (Cheniere Holdings) owns and operates the Sabine Pa …
  • Crossject SA (ALCJ)-医療機器分野：企業M&A・提携分析
    Summary Crossject SA (Crossject) is a medical device company that develops injection systems. The company offers products which include methotrexate, epinephrin, sumatriptan, L15, naloxone, apomorphine, and midazolam. It uses its needle-free injection system to develop a pipeline of supergenerics by …
  • Pareteum Corp (TEUM)：企業の財務・戦略的SWOT分析
    Pareteum Corp (TEUM) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Cumberland Pharmaceuticals Inc (CPIX)-製薬・医療分野：企業M&A・提携分析
    Summary Cumberland Pharmaceuticals Inc (Cumberland Pharma) is a pharmaceutical company which develops and commercializes branded prescription products. The company’s product portfolio includes acetylcysteine, ibuprofen, lactulose, conivaptan, amifostine and ifetroban. It provides prescription produc …
  • Sa Sa International Holdings Limited (178)：企業の財務・戦略的SWOT分析
    Sa Sa International Holdings Limited (178) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengt …
  • Navidea Biopharmaceuticals Inc (NAVB)-医療機器分野：企業M&A・提携分析
    Summary Navidea Biopharmaceuticals Inc (Navidea) is a precision medicine company that focuses on the development and commercialization of radiopharmaceutical agents and precision diagnostics. Its key product, Lymphoseek (technetium Tc 99m tilmanocept) injection, is a radiopharmaceutical agent used i …
  • Scholastic Corporation：企業の戦略・SWOT・財務情報
    Scholastic Corporation - Strategy, SWOT and Corporate Finance Report Summary Scholastic Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • The Boeing Co (BA)：企業の財務・戦略的SWOT分析
    The Boeing Co (BA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …
  • TMRC Co Ltd-製薬・医療分野：企業M&A・提携分析
    Summary TMRC Co Ltd (TMRC) is a biopharmaceutical company that develops and markets anti-cancer and cancer related products. The company’s products include tamibarotene Am-80, TOS-80T, OMS0728, and others. Its tamibarotene is a synthetic retinoid, which is designed to develop drug-able properties of …
  • 3M India Limited (3MINDIA)：企業の財務・戦略的SWOT分析
    3M India Limited (3MINDIA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • Travelsky Technology Ltd (696)：企業の財務・戦略的SWOT分析
    Travelsky Technology Ltd (696) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakn …
  • IAV GmbH：企業の戦略的SWOT分析
    IAV GmbH - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. Thi …
  • Concept Life Sciences Ltd-製薬・医療分野：企業M&A・提携分析
    Summary Concept Life Sciences Ltd (Concept Life Sciences), formerly Peakdale Molecular Ltd, a subsidiary of Concept Life Sciences Holdings Ltd is a provider of integrated discovery and development solution. The company services include integrated drug discovery and development services and analytica …
  • PeptiDream Inc (4587)-製薬・医療分野：企業M&A・提携分析
    Summary PeptiDream Inc (PeptiDream) is a biopharmaceutical company that discovers and develops constrained peptides, small molecule, and peptide-drug conjugate therapeutics. The company develops peptide discovery platform system (PDPS), a peptide generation and selection platform. Its technologies i …
  • Lonrho Ltd：企業のM&A・事業提携・投資動向
    Lonrho Ltd - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Lonrho Ltd Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capi …

◆H&Iグローバルリサーチ株式会社のお客様（例）◆